Oxybutynin Chloride
Product Images NDC 68151-3646

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Oxybutynin Chloride (NDC 68151-3646). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl681513646)

OXYBUTYNIN CHLORIDE Extended-Release 5 mg tablet label showing manufacturer IMPAX, lot number 10007041, expiration date 09/14, barcode, and NDC 68151-3646. The label indicates prescription use only and includes additional manufacturing codes.*

FDA Label Image

Chemical Structure (Oxybutynin Chloride Extended Release Tablets 1)

Chemical structure of Oxybutynin Chloride showing its molecular components including phenyl, cyclohexyl, ester, ethynyl, and diethylamine groups with a hydrochloride component.*

FDA Label Image

Figure 1 (Oxybutynin Chloride Extended Release Tablets 2)

A line chart comparing mean plasma R-Oxybutynin concentration (ng/mL) over 24 hours for oxybutynin chloride extended-release tablets 10 mg once daily (QD) versus oxybutynin 5 mg three times daily (TID). The x-axis shows time in hours, and the y-axis shows concentration with error bars indicating variability.*

FDA Label Image

Figure 2 (Oxybutynin Chloride Extended Release Tablets 3)

A line graph depicting the mean R-Oxybutynin plasma concentration (ng/mL) over time (hours). The graph shows plasma concentration values measured at several time points up to 24 hours, with error bars indicating variability at each point.*

FDA Label Image

Figure (Oxybutynin Chloride Extended Release Tablets 4)

A horizontal error bar chart comparing mean change with standard deviation (±SD) in episodes per week from baseline between Oxybutynin Chloride Extended Release Tablets and placebo. The x-axis ranges from -40 to 40 episodes per week, showing the comparative effect size and variability for each group.*

FDA Label Image

Figure (Oxybutynin Chloride Extended Release Tablets 5)

A horizontal error bar chart illustrating the mean change with standard deviation in episodes per week from baseline for Oxybutynin Chloride Extended Release Tablets and Oxybutynin. The x-axis ranges from -40 to 40, showing the reduction in episodes.*

FDA Label Image

Figure (Oxybutynin Chloride Extended Release Tablets 6)

A horizontal bar chart illustrating mean change (±SD) in episodes per week from baseline. It compares Oxybutynin Chloride Extended Release Tablets and Oxybutynin, showing a negative mean change indicating reduction in episodes. The x-axis ranges from -40 to 40 changes per week.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.